Pulmonary sarcoidosis: A comprehensive review: Past to present
CONCLUSION: The mortality rate for sarcoidosis over a 5 year follow up is approximately 7%. Unfortunately, 10%-40% of patients with sarcoidosis develop progressive pulmonary disease, and >60% of deaths resulting from sarcoidosis are due to advance cardiopulmonary disease. Oral glucocorticoids are the first line treatment, while methotrexate and azathioprine are considered second and anti-TNF agents are third line treatments that are used solely or as glucocorticoid sparing agents for symptomatic extrapulmonary or pulmonary sarcoidosis with infiltrates on chest radiographs and abnormal PFT. Relapse rates have ranged from 13% to 75% depending on the population studied.PMID:37865579 | DOI:10.1016/j.jaut.2023.103107
Source: Journal of Autoimmunity - Category: Allergy & Immunology Authors: John A Belperio Michael C Fishbein Fereidoun Abtin Jessica Channick Shailesh A Balasubramanian Joseph P Lynch Iii Source Type: research
More News: Allergy & Immunology | Cardiology | Cough | Heart | Hypertension | Japan Health | Methotrexate | Prednisone | Pulmonary Hypertension | Radiography | Respiratory Medicine | Sarcoidosis | Spirometry